SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-055793
Filing Date
2021-02-25
Accepted
2021-02-25 08:04:17
Documents
13
Period of Report
2021-02-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d102341d8k.htm   iXBRL 8-K 26246
2 EX-99.1 d102341dex991.htm EX-99.1 76049
  Complete submission text file 0001193125-21-055793.txt   235512

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA akba-20210225.xsd EX-101.SCH 3051
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20210225_lab.xml EX-101.LAB 17373
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20210225_pre.xml EX-101.PRE 10940
6 EXTRACTED XBRL INSTANCE DOCUMENT d102341d8k_htm.xml XML 3236
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 21676477
SIC: 2834 Pharmaceutical Preparations